

## CAPITAL AND BUSINESS TIE-UP WITH SUSMED, INC.

Nippon Chemiphar Co., Ltd.

(TSE: 4539)

August 24, 2020

Nippon Chemiphar Co., Ltd. (hereinafter, “Chemiphar”), announced today that it has accepted a portion of a third-party allocation of shares from SUSMED, Inc. (hereinafter, “SUSMED”), and has launched a business tie-up with SUSMED that will focus on the joint development of candidate prescription drugs for potential use in specific therapeutic areas.

### 1. Purpose

SUSMED is a research and development company that is firmly supported by a variety of patents associated with therapeutic apps and medical applications for blockchain technology. It develops therapeutic apps for conditions such as insomnia and provides a universal platform for the development of therapeutic apps, a clinical development support system and an AI-based automatic analysis system.

We decided to start a business and capital tie-up with SUSMED because of their highly praiseworthy technology, expertise and potential. Our capital participation in SUSMED is cultivating further mutual collaboration and expansion.

### 2. Details

On August 21, we concluded an agreement to accept a portion of a third-party allocation of shares from SUSMED. We have not disclosed the amount of investment or other terms and conditions.

### 3. Outline of SUSMED

Company Name	SUSMED, Inc.
CEO	Taro Ueno
Head office	Chuo-ku, Tokyo, Japan
Paid in Capital	¥813 million
Established	February 2016
URL	<a href="https://www.susmed.co.jp/en">https://www.susmed.co.jp/en</a>

**For further information contact:** E-mail: [ir@chemiphar.co.jp](mailto:ir@chemiphar.co.jp)

Public Relations Department, Nippon Chemiphar Co., Ltd.